Patient tumor biopsies were analyzed using whole-exome sequencing, RNA-seq, proteomic, and phosphoproteomic analysis to describe TRAF2 status.Proteomic analysis identified three groups reflecting distinct clinical prognoses and molecular signatures. Immune subtypes of UC tumors revealed a complex immune landscape and suggested that TRAF2 amplification is related to the increased expression of PD-L1. Increased GARS was validated to promote the pentose phosphate pathway by inhibiting activities of PGK1 and PKM2. This evidence concerns the gene PKM and neoplasm.